Articles related to Pharmacy (Clinical/Hospital)

The FDA has approved once-monthly subcutaneous olanzapine for adults with schizophrenia, supported by placebo-controlled trial data showing symptom improvement and sustained efficacy through 48 weeks, while eliminating several logistical requirements associated with treatment initiation.

The FDA has approved tavapadon, a selective D1/D5 dopamine receptor partial agonist, for adults with Parkinson disease following phase 3 studies demonstrating benefit both as monotherapy in early disease and as adjunctive therapy to levodopa.

Healthcare leaders speaking at AXS26 argued that artificial intelligence tools affecting patient care require stronger oversight, including independent validation, bias monitoring, and human review. The discussion highlighted both operational opportunities and safety concerns surrounding healthcare AI adoption.

Attorneys speaking at a specialty pharmacy meeting warned that increased federal attention to fraud, waste, abuse, controlled substances, and reimbursement practices is driving greater scrutiny of pharmacies. The discussion focused on compliance preparedness rather than new regulatory requirements.

The FDA classified a recall of thyroid tablets USP 30 mg as Class I after identification of a superpotent product lot. The recall affects 1,955 bottles and carries risk of serious adverse health consequences, making prompt inventory review and product removal necessary.

A novel liposomal drug-delivery system prolonged tetrodotoxin nerve blockade to two to three weeks in rats, substantially exceeding currently available formulations. The findings highlight a potential strategy for sustained local anesthetic delivery, although clinical relevance remains unproven pending human validation.